

# Pembrolizumab (Keytruda®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » Nicht-Plattenepithelkarzinom, Kombination » Erstlinie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

## **Herausgeber**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Bauhofstr. 12  
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Hermann Einsele

Telefon: +49 (0)30 27 87 60 89 - 0

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Ansprechpartner**

Prof. Dr. med. Bernhard Wörmann  
Medizinischer Leiter

## **Quelle**

[www.onkopedia.com](http://www.onkopedia.com)

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

# Inhaltsverzeichnis

<b>1 Pembrolizumab, NSCLC, non-squamous, combination, first line</b>	<b>... 2</b>
--	--------------

# Pembrolizumab (Keytruda®)

**Dokument:** Fact Sheet

**Spezifizierung:** Lungenkarzinom, nicht-kleinzellig (NSCLC) » Nicht-Plattenepithelkarzinom, Kombination » Erstlinie

**Stand:** Juli 2021

## 1 Pembrolizumab, NSCLC, non-squamous, combination, first line

Pembrolizumab, NSCLC, non-squamous, combination, first line																																													
onkopedia		Facts	Appraisal																																										
		EU Approval 2019																																											
<b>Parameter</b>	<b>Results<sup>14</sup></b>	<b>HR<sup>15</sup></b>	<b>p value</b>																																										
RR <sup>2</sup>	18.4 vs 47.6																																												
PFS <sup>3</sup>	4.9 vs 8.8	0.48	p < 0.001																																										
OS <sup>5</sup>	10.7 vs 22.0	0.56	p < 0.001																																										
SAE <sup>7</sup>	65.8 vs 67.2																																												
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">5</td><td style="width: 10%;">4</td><td style="width: 10%;">3b</td><td style="width: 10%;">3a</td><td style="width: 10%;">2c</td><td style="width: 10%;">2b</td><td style="width: 10%;">2a</td><td style="width: 10%;">1b</td><td style="width: 10%;">1a</td> </tr> <tr> <td colspan="9" style="text-align: center;">Evidence (LoE)</td> </tr> <tr> <td colspan="9" style="text-align: center;"> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">1</td><td style="width: 20%;">2</td><td style="width: 20%;">3</td><td style="width: 20%;">4</td><td style="width: 20%;">5</td> </tr> <tr> <td colspan="5" style="text-align: center;">Clinical benefit (ESMO MCBS)</td> </tr> <tr> <td colspan="5" style="text-align: center;"> <div style="display: flex; justify-content: space-around; align-items: center;"> <span style="color: blue;">■</span> curative                             <span style="color: yellow;">■</span> non-curative                         </div> </td> </tr> </table> </td> </tr> </table>				5	4	3b	3a	2c	2b	2a	1b	1a	Evidence (LoE)									<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">1</td><td style="width: 20%;">2</td><td style="width: 20%;">3</td><td style="width: 20%;">4</td><td style="width: 20%;">5</td> </tr> <tr> <td colspan="5" style="text-align: center;">Clinical benefit (ESMO MCBS)</td> </tr> <tr> <td colspan="5" style="text-align: center;"> <div style="display: flex; justify-content: space-around; align-items: center;"> <span style="color: blue;">■</span> curative                             <span style="color: yellow;">■</span> non-curative                         </div> </td> </tr> </table>									1	2	3	4	5	Clinical benefit (ESMO MCBS)					<div style="display: flex; justify-content: space-around; align-items: center;"> <span style="color: blue;">■</span> curative                             <span style="color: yellow;">■</span> non-curative                         </div>				
5	4	3b	3a	2c	2b	2a	1b	1a																																					
Evidence (LoE)																																													
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">1</td><td style="width: 20%;">2</td><td style="width: 20%;">3</td><td style="width: 20%;">4</td><td style="width: 20%;">5</td> </tr> <tr> <td colspan="5" style="text-align: center;">Clinical benefit (ESMO MCBS)</td> </tr> <tr> <td colspan="5" style="text-align: center;"> <div style="display: flex; justify-content: space-around; align-items: center;"> <span style="color: blue;">■</span> curative                             <span style="color: yellow;">■</span> non-curative                         </div> </td> </tr> </table>									1	2	3	4	5	Clinical benefit (ESMO MCBS)					<div style="display: flex; justify-content: space-around; align-items: center;"> <span style="color: blue;">■</span> curative                             <span style="color: yellow;">■</span> non-curative                         </div>																										
1	2	3	4	5																																									
Clinical benefit (ESMO MCBS)																																													
<div style="display: flex; justify-content: space-around; align-items: center;"> <span style="color: blue;">■</span> curative                             <span style="color: yellow;">■</span> non-curative                         </div>																																													
<b>Patients</b> first line, non squamous <b>Trial</b> KEYNOTE-189, phase 3 <b>Randomisation</b> 1 : 1 <b>N<sup>1</sup></b> 616 <b>New Therapy</b> Platin + Pemetrexed <b>Control</b> Platin + Pemetrexed + Pembrolizumab <b>Publication</b> DOI:10.1056/NEJMoa1801005		<b>Additional benefit (G-BA)</b> lower proven not quantifiable not minor considerable major PD-L1 <50% PD-L1 ≥50%																																											

Legende:

<sup>1</sup> N - number of patients

<sup>2</sup> RR - remission rate, in %

<sup>3</sup> PFS - progression-free survival in months

<sup>5</sup> OS - overall survival in months

<sup>7</sup> SAE - serious adverse events, CTCAE grade 3/4

<sup>14</sup> results for control, results for new therapy

<sup>15</sup> hazard ratio for new therapy